Mays Cancer Center conducts only clinical trial in America of a specific drug combination for lethal brain cancer glioblastoma

May 23, 2023

An improvement in 6-month progression-free survival warrants additional study in a larger trial, researchers said. The Mays Cancer Center at The University of Texas Health Science Center at San Antonio recently conducted a clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma (GBM). The Mays Cancer Center, one of the four National Cancer […]

Statement from the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at The University of Texas Health Science Center at San Antonio about the study drug donanemab

May 23, 2023

  Alicia S. Parker, MD, of The University of Texas Health Science Center at San Antonio, is assistant professor of cognitive and behavioral neurology and clinic director for the health science center’s Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases. The Biggs Institute, in partnership with The University of Texas Rio Grande Valley, is Texas’ […]

Mays Cancer Center conducts only clinical trial in America of a specific drug combination for lethal brain cancer glioblastoma

May 23, 2023

An improvement in 6-month progression-free survival warrants additional study in a larger trial, researchers said. Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (May 23, 2023) — The Mays Cancer Center at The University of Texas Health Science Center at San Antonio recently conducted a clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma […]

Statement by the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases about the study drug donanemab

May 22, 2023

Media contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (May 22, 2023) — Alicia S. Parker, MD, of The University of Texas Health Science Center at San Antonio, is assistant professor of cognitive and behavioral neurology and clinic director for the health science center’s Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases. The Biggs Institute, in […]

Molecule shows potential to combat treatment resistance in brain tumor glioblastoma

May 17, 2023

Glioblastoma-impacted mice lived longer when treated with combination of molecule drug and chemotherapy agent Glioblastoma (GBM), a highly devastating brain tumor, has long posed challenges as effective treatments have remained elusive. Despite responding initially to treatment, GBM patients often experience therapy resistance leading to low long-term survival rates, with only 7.2% of patients surviving beyond […]

Molecule shows potential to combat treatment resistance in brain tumor glioblastoma

May 17, 2023

Glioblastoma-impacted mice lived longer when treated with combination of molecule drug and chemotherapy agent Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (May 17, 2023) — Glioblastoma (GBM), a highly devastating brain tumor, has long posed challenges as effective treatments have remained elusive. Despite responding initially to treatment, GBM patients often experience therapy resistance leading to […]